Abstract
Overview
Introduction
The continued uptake of existing brands and the launch of two opioid
antagonists will cause the market to grow at a compound annual growth rate of
13.5% from 2006 to reach $304m across the seven major markets by 2016. The
alcohol dependence market requires a paradigm shift away from the public
perception that it is a behavioral disorder towards being regarded as a
treatable medical condition.
Scope
- Analysis of epidemiology, unmet needs and clinical trial design in alcohol
dependence with insight from key opinion leaders
- Overview of the current alcohol dependence market.
- Analysis of patient potential, marketing factors, commercial
attractiveness and clinical attractiveness of key late-stage pipeline drugs.
- Indication-specific forecasts of key drug key late-stage pipeline drugs
revenues to 2016.
Report Highlights
The current alcohol dependence pipeline is small in comparison to other
central nervous system markets. Opioid antagonists are the most prevalent drug
class in late-stage development and include two reformulations of naltrexone.
Datamonitor therefore believes the current alcohol dependence pipeline to be
weak and lacking in innovation.
The efficacy of currently marketed pharmaceutical products is limited, thereby
leaving market opportunity for new therapies. Furthermore, in view of the poor
medication compliance rate in alcohol dependent patients, pipeline drugs that
possess the potential to improve patient compliance can expect to receive a
strong uptake.
Companies developing naltrexone depot drugs will experience difficulty
distinguishing their products from Vivitrol (naltrexone once-monthly
controlled-release, Alkermes/Cephalon) unless they price their drugs
competitively and/or incorporate an injection device that produces less pain
and fewer injection site reactions.
Reasons to Purchase
- Understand unmet needs and opportunities in this market based on the
comments of interviewed key opinion leaders.
- Benchmark key late-stage alcohol dependence compounds against the current
market leader.
- Assess the seven major market total sales forecasts of key late-stage
pipeline drugs; and examine their clinical and commercial potential.
View Cart
